Author: Ken Dropiewski

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction

Iocyte AMI-3 Trial to Assess Effectiveness and Safety of FDY-5301 in Improving Outcomes for Anterior STEMI Patients Undergoing Primary PCI SEATTLE, May 10, 2022 (GLOBE NEWSWIRE) — Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the efficacy […]

InspireMD Reports First Quarter 2022 Financial Results and Business Update

         – 20% growth in CGuard™ revenue Year-over-Year –            – C-Guardian FDA IDE Trial Completes First European Enrollment –            – Held Key Opinion Leader (KOL) Webinar on Carotid Artery Disease Management and Stroke Prevention, highlighting CGuard™ clinical advantages –            – European logistics hub established with BOMI Group –for direct market access as […]

Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

First quarter 2022 results reflect strong CAPLYTA® (lumateperone) launch in bipolar depression First quarter 2022 CAPLYTA new and total prescriptions increased 63% and 45%, respectively, versus the fourth quarter 2021 First quarter 2022 CAPLYTA new and total prescriptions increased 154% and 134%, respectively, versus the same period in 2021 New-to-brand CAPLYTA […]

Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results

Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory Filings for VERVE-101 in Second Half of 2022 Cash, Cash Equivalents and Marketable Securities […]

CinCor Reports First Quarter Financial Results and Provides Corporate Update

Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for uncontrolled hypertension (uHTN) expected in 2H 2022 Phase 2 figHTN-CKD trial evaluating baxdrostat’s (CIN-107) utility in ameliorating complications of chronic kidney […]

Aziyo Biologics Provides Business Update and Reports First Quarter 2022 Financial Results

SILVER SPRING, Md., May 09, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today provided a business update and reported financial results for the first quarter March 31, […]

Quanterix Corporation Releases Operating Results for First Quarter 2022

Quanterix reports continued revenue growth as it scales to support transformational advances in neurology research BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the three months ended March 31, 2022. “This is a […]

CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System

Heart failure patients implanted with Barostim can now receive conditional MRI scans MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) —  CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. Food and Drug Administration (FDA) approval for magnetic resonance […]

HealthWell Foundation Launches Fund to Assist Individuals Living with Cardiomyopathy

Medication Copayment and Insurance Premium Assistance Now Available for Medicare Patients GERMANTOWN, Md., May 9, 2022 /PRNewswire/ — The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is pleased to announce that it has opened a new fund to assist individuals living with cardiomyopathy. Through the new […]

Humacyte to Provide Human Acellular Vessels™ (HAVs™) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries

— First shipment of HAVs to six Ukrainian hospitals made today — — Product candidate to be used for civilian and military vascular trauma repair, the HAV’s lead investigational indication — DURHAM, N.C., May 09, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally […]